Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Price:
16.83
CNY
-10.38%
Market Closed
Market Cap:
8.3B
CNY
Income Statement
Earnings Waterfall
Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co Ltd
|
Revenue
|
2.9B
CNY
|
|
Cost of Revenue
|
-796.4m
CNY
|
|
Gross Profit
|
2.1B
CNY
|
|
Operating Expenses
|
-1.6B
CNY
|
|
Operating Income
|
559.3m
CNY
|
|
Other Expenses
|
-51.3m
CNY
|
|
Net Income
|
508m
CNY
|
Income Statement
Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co Ltd
Currency: CNY
Millions
TTM
| Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||||||||
| Revenue |
430
N/A
|
472
+10%
|
535
+13%
|
613
+15%
|
680
+11%
|
746
+10%
|
801
+7%
|
811
+1%
|
867
+7%
|
899
+4%
|
924
+3%
|
906
-2%
|
891
-2%
|
921
+3%
|
978
+6%
|
1 096
+12%
|
1 317
+20%
|
1 451
+10%
|
1 628
+12%
|
1 799
+11%
|
1 927
+7%
|
2 097
+9%
|
2 326
+11%
|
2 379
+2%
|
2 513
+6%
|
2 620
+4%
|
2 693
+3%
|
2 782
+3%
|
2 841
+2%
|
2 945
+4%
|
|
| Gross Profit | |||||||||||||||||||||||||||||||
| Cost of Revenue |
(217)
|
(241)
|
(258)
|
(291)
|
(309)
|
(320)
|
(324)
|
(327)
|
(336)
|
(328)
|
(302)
|
(297)
|
(262)
|
(253)
|
(253)
|
(274)
|
(316)
|
(338)
|
(365)
|
(404)
|
(445)
|
(485)
|
(523)
|
(576)
|
(591)
|
(619)
|
(622)
|
(686)
|
(746)
|
(796)
|
|
| Gross Profit |
213
N/A
|
231
+8%
|
277
+20%
|
322
+16%
|
371
+15%
|
427
+15%
|
477
+12%
|
484
+1%
|
532
+10%
|
571
+7%
|
622
+9%
|
610
-2%
|
629
+3%
|
668
+6%
|
725
+8%
|
822
+13%
|
1 001
+22%
|
1 113
+11%
|
1 262
+13%
|
1 394
+10%
|
1 482
+6%
|
1 612
+9%
|
1 804
+12%
|
1 804
0%
|
1 922
+7%
|
2 001
+4%
|
2 071
+3%
|
2 095
+1%
|
2 095
+0%
|
2 149
+3%
|
|
| Operating Income | |||||||||||||||||||||||||||||||
| Operating Expenses |
(142)
|
(150)
|
(193)
|
(244)
|
(293)
|
(356)
|
(399)
|
(408)
|
(455)
|
(492)
|
(555)
|
(545)
|
(552)
|
(583)
|
(628)
|
(680)
|
(813)
|
(884)
|
(1 026)
|
(1 147)
|
(1 223)
|
(1 330)
|
(1 500)
|
(1 480)
|
(1 559)
|
(1 583)
|
(1 673)
|
(1 632)
|
(1 584)
|
(1 590)
|
|
| Selling, General & Administrative |
(143)
|
(150)
|
(163)
|
(207)
|
(248)
|
(293)
|
(340)
|
(351)
|
(376)
|
(401)
|
(451)
|
(448)
|
(466)
|
(508)
|
(554)
|
(608)
|
(728)
|
(787)
|
(894)
|
(991)
|
(1 052)
|
(1 149)
|
(1 315)
|
(1 298)
|
(1 378)
|
(1 380)
|
(1 435)
|
(1 415)
|
(1 354)
|
(1 374)
|
|
| Research & Development |
0
|
0
|
(26)
|
(37)
|
(48)
|
(65)
|
(52)
|
(65)
|
(85)
|
(99)
|
(97)
|
(110)
|
(98)
|
(92)
|
(70)
|
(91)
|
(103)
|
(113)
|
(136)
|
(157)
|
(174)
|
(184)
|
(183)
|
(210)
|
(208)
|
(230)
|
(237)
|
(252)
|
(277)
|
(264)
|
|
| Depreciation & Amortization |
0
|
0
|
(8)
|
0
|
0
|
0
|
(12)
|
0
|
0
|
0
|
(20)
|
0
|
0
|
0
|
(23)
|
0
|
0
|
0
|
(21)
|
0
|
0
|
0
|
(28)
|
0
|
0
|
0
|
(29)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
1
|
(0)
|
3
|
(1)
|
2
|
2
|
5
|
7
|
6
|
8
|
14
|
13
|
13
|
17
|
18
|
19
|
18
|
15
|
25
|
1
|
4
|
3
|
25
|
27
|
27
|
27
|
29
|
36
|
47
|
48
|
|
| Operating Income |
70
N/A
|
80
+14%
|
84
+4%
|
79
-6%
|
78
-1%
|
71
-9%
|
79
+11%
|
77
-3%
|
77
+1%
|
79
+3%
|
67
-15%
|
64
-4%
|
77
+20%
|
85
+10%
|
97
+13%
|
142
+48%
|
188
+32%
|
228
+21%
|
236
+4%
|
247
+5%
|
259
+5%
|
282
+9%
|
303
+7%
|
323
+7%
|
362
+12%
|
418
+15%
|
398
-5%
|
464
+16%
|
511
+10%
|
559
+9%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||||||||
| Interest Income Expense |
(1)
|
(1)
|
(0)
|
0
|
1
|
2
|
2
|
0
|
(1)
|
(3)
|
(4)
|
(5)
|
(6)
|
(5)
|
(5)
|
(4)
|
(7)
|
(9)
|
(10)
|
(13)
|
(12)
|
(13)
|
(12)
|
(8)
|
(4)
|
(2)
|
(4)
|
(8)
|
(11)
|
(12)
|
|
| Non-Reccuring Items |
0
|
0
|
(10)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
2
|
3
|
4
|
1
|
2
|
1
|
1
|
(2)
|
(2)
|
(4)
|
(1)
|
(4)
|
(4)
|
(4)
|
1
|
0
|
(0)
|
(0)
|
2
|
(1)
|
0
|
0
|
0
|
(1)
|
8
|
9
|
9
|
6
|
(3)
|
(3)
|
|
| Pre-Tax Income |
71
N/A
|
83
+16%
|
77
-7%
|
80
+4%
|
80
+0%
|
74
-8%
|
79
+8%
|
75
-6%
|
74
-1%
|
73
-2%
|
59
-19%
|
55
-6%
|
68
+23%
|
76
+12%
|
91
+19%
|
138
+52%
|
181
+31%
|
219
+21%
|
226
+3%
|
234
+3%
|
247
+5%
|
269
+9%
|
290
+8%
|
314
+8%
|
366
+17%
|
424
+16%
|
402
-5%
|
462
+15%
|
496
+7%
|
543
+9%
|
|
| Net Income | |||||||||||||||||||||||||||||||
| Tax Provision |
(9)
|
(10)
|
(8)
|
(9)
|
(8)
|
(7)
|
(7)
|
(6)
|
(2)
|
(7)
|
(4)
|
(3)
|
(8)
|
(4)
|
(9)
|
(16)
|
(19)
|
(23)
|
(22)
|
(20)
|
(26)
|
(26)
|
(21)
|
(23)
|
(29)
|
(53)
|
(34)
|
(45)
|
(42)
|
(35)
|
|
| Income from Continuing Operations |
62
|
72
|
69
|
71
|
72
|
67
|
72
|
70
|
73
|
65
|
55
|
52
|
59
|
72
|
82
|
122
|
162
|
196
|
204
|
214
|
221
|
243
|
270
|
291
|
338
|
371
|
368
|
417
|
455
|
508
|
|
| Net Income (Common) |
62
N/A
|
72
+17%
|
69
-5%
|
71
+4%
|
72
+1%
|
67
-7%
|
72
+8%
|
70
-3%
|
73
+4%
|
65
-10%
|
55
-16%
|
52
-6%
|
59
+15%
|
72
+22%
|
82
+14%
|
122
+48%
|
162
+33%
|
196
+21%
|
204
+4%
|
214
+5%
|
221
+3%
|
243
+10%
|
270
+11%
|
291
+8%
|
338
+16%
|
371
+10%
|
368
-1%
|
417
+13%
|
455
+9%
|
508
+12%
|
|
| EPS (Diluted) |
0.36
N/A
|
0.41
+14%
|
0.36
-12%
|
0.3
-17%
|
0.33
+10%
|
0.28
-15%
|
0.31
+11%
|
0.3
-3%
|
0.31
+3%
|
0.28
-10%
|
0.23
-18%
|
0.22
-4%
|
0.25
+14%
|
0.31
+24%
|
0.35
+13%
|
0.53
+51%
|
0.49
-8%
|
0.59
+20%
|
0.44
-25%
|
0.65
+48%
|
0.67
+3%
|
0.74
+10%
|
0.59
-20%
|
0.84
+42%
|
1.01
+20%
|
0.75
-26%
|
0.76
+1%
|
0.85
+12%
|
0.94
+11%
|
1.05
+12%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
